Beam Therapeutics Analyst Ratings
H.C. Wainwright Initiates Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $80
Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
Beam Therapeutics: A Hold Rating Amid Controlled R&D Spending and Upcoming Clinical Milestones
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
Beam Therapeutics Analyst Ratings
Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $33
Beam Therapeutics Analyst Ratings
Beam Therapeutics: A Buy Rating Amidst Gene Editing Industry Developments
Beam Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
Beam Therapeutics: Financial and Clinical Prospects Inform Hold Rating
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating
Beam Therapeutics Analyst Ratings
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), Beam Therapeutics (BEAM) and Opko Health (OPK)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Beam Therapeutics (BEAM), ACADIA Pharmaceuticals (ACAD) and Recursion Pharmaceuticals (RXRX)
Beam Therapeutics: Strong Buy Rating on Impressive Q4 Earnings and Promising Pipeline Developments
Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)
William Blair Keeps Their Buy Rating on Beam Therapeutics (BEAM)